Collaborations are common in drug development. In most cases, the partners have similar goals — to develop and market a product — but their sensitivities around public disclosures about the collaboration may be very different. For instance, what is material to a small company with only a few products under development may be immaterial to a pharmaceutical giant. In addition, publicly traded companies will have disclosure obligations that privately held companies will not need to worry about.
Join Pepper Hamilton partners Timothy C. Atkins and Scott R. Jones as they discuss issues that may arise in connection with the disclosure obligations of collaboration partners. In particular, this event will cover how to draft provisions into the collaboration agreement to account for disclosure obligations of the parties, seeking confidential treatment for the collaboration agreement when the agreement must be filed with the SEC by at least one of the parties to the collaboration, and how to handle disclosure issues as the collaboration progresses.
This seminar is approved for one substantive CLE credit in Pennsylvania. Attorneys licensed in New Jersey may claim credit for this program under New Jersey's reciprocity policy.
This event is sponsored by Pepper Hamilton's Health Sciences Department, a team of 110 attorneys who collaborate across disciplines to solve complex legal challenges confronting clients throughout the health sciences spectrum.
Philadelphia Country Club
1601 Spring Mill Road
Gladwyne, PA 19035
There is no cost to attend.
Contact Kim MacAlister at email@example.com or 215.981.4249 with any questions.